      Document 0023
 DOCN  DRG0023
 UNIQUE IDENTIFIER        DRG-0224
 NAME OF SUBSTANCE        HIV-1 C4-V3 Polyvalent Peptide Vaccine [NIAID
                          DATRI 010]
 PROTOCOL ID NUMBERS      NIAID DATRI 010
 SECONDARY SOURCE ID      DRG
 PHARMACOLOGICAL ACTION   MODE OF ACTION: Potential induction of
                          cross-reactive antibody responses. The
                          vaccine is composed of selected gp120
                          epitopes T1, SP10, and A. The peptide
                          sequences represent the minimally sufficient
                          epitopes necessary to generate neutralizing
                          antibody, MHC class I-restricted cytotoxic
                          T-lymphocyte (CTL), and helper cell
                          responses. The SP10 (A) portions of gp120 are
                          amino acids 303-327, representing V3 loop
                          epitopes important for neutralizing
                          antibodies, and the T1 portion is amino acids
                          428-443, a helper T-cell epitope. The section
                          of SP10 (A) composed of amino acids 304-313
                          is an important epitope for MHC class
                          I-restricted CTL responses in individuals
                          with HLA-B7 phenotype. The HIV-1 C4-V3
                          polyvalent peptide vaccine not only utilizes
                          epitopes from gp120 but also is a prototype
                          multivalent immunogen containing the amino
                          acid sequences for selected epitopes from
                          four of the most common HIV isolates in the
                          United States and Europe -- EV91, MN, RF, and
                          CAN0 -- which are predicted to represent
                          50-90% of the HIV isolates in the United
                          States.[NIAID DATRI 010]
 DISEASES STUDIED/TREATED Primary HIV infection [NIAID DATRI 010]
 CLASSIFICATION CODE      Vaccine [NIAID DATRI 010]
 ADVERSE EFFECTS          Anticipated adverse effects include local
                          reactions at the injection site, such as
                          discomfort, pain tendernes, swelling,
                          itching, skin dicoloration, and drainage of
                          clear fluid. Also, fever, fatigue, or body
                          aches (flu-like symptoms) may occur.[NIAID
                          DATRI 010]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: Synthetic polyvalent
                          peptide vaccine
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Subcutaneous. [NIAID DATRI
                          010]
 MANUFACTURERS            Lederle-Praxis Biologicals
 REFERENCES               Haynes BF, Moody MA, Heinley CS, Korber B,
                          Millard WA, Scearce RM. HIV type 1 V3 region
                          primer-induced antibody suppression is
                          overcome by administration of C4-V3 peptides
                          as a polyvalent immunogen. AIDS Res Hum
                          Retroviruses. 1995 Feb;11(2)211-21.
 ENTRY MONTH              9506
 LAST REVISION DATE       960424
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
